Larimar Therapeutics (LRMR) Stock Analysis
NASDAQHealthcareBiotechnology
What Larimar Therapeutics does
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Key metrics
ETFs linked to LRMR
Broad-market and Healthcare sector ETFs an investor holding Larimar Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how LRMR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze LRMR in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Larimar Therapeutics?
- Larimar Therapeutics trades under the ticker LRMR on NASDAQ.
- Which exchange is LRMR listed on?
- LRMR is listed on NASDAQ.
- What sector does Larimar Therapeutics operate in?
- Larimar Therapeutics is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze LRMR in a portfolio?
- PortView shows LRMR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.